Great graphics and global overview on cancer prevalence and therapeutic improvements in this article. Overall cancer survival rates have moved from 50% end of the 70s to 67% in 2013. https://t.co/VAxJFDxz5j

mRNA vaccines as unplanned immunotherapy primers ⚡ SARS-CoV-2 mRNA vaccination triggers a type I IFN surge, activates APCs, and primes CD8⁺ T cells for tumor antigen recognition. 🧩 IFN-driven PD-L1 upregulation 🧭 Enhanced T-cell infiltration into “cold” tumors 🌐

Its time to have another community Fan Art event where you make the art, and the community votes their favorite! The top 5 art pieces will be receiving the rewards! RULES: - Anything Hero Siege related - No NSFW - No AI (we will filter these out) - Post progress pictures, at

ADCs biology is shaped by antibody, linker stability, payload, & immune synergy 🌊 Systemic kinetics: DAR balance critical; high DAR → higher clearance/toxicity, low DAR → weak efficacy 🔀 Linker chemistry controls payload release: cleavable vs non-cleavable,

ADCs are not just “guided missiles” — new biology is reshaping how we view them 🌊 Continuous payload exposure in circulation sustains cytotoxic thresholds 🔀 Antigen level ≠ response: extracellular cleavage enables efficacy in “HER2-null” tumors 🛡️ Fc functions &

Mismatch Repair Deficiency: From DNA repair failure to immunotherapy sensitivity 🌊 Loss of MMR → microsatellite instability → hypermutation → abundant neoantigens 🛡️ Immune context: TIL-rich & inflamed, but immune checkpoints (PD-1, CTLA4, LAG3) and fibrotic stroma

Circulating Tumor Cells: Mechanistic drivers of metastasis & biomarker promise 🌊 Intravasation via EMT/VEGF; clusters = 25–50× ↑ metastasis 🔀 Lineage plasticity (epithelial ↔ mesenchymal ↔ neuroendocrine) 🛡️ Platelets & neutrophils shield CTCs; PD-L1+ escape 🧬

Circulating Tumor Cells: Beyond ctDNA in Precision Oncology 🩸CTCs ≠ ctDNA: Beyond mutations, CTCs reveal real-time protein & RNA expression—useful for target discovery & resistance monitoring. 🔬 Liquid biopsy advantage: Noninvasive CTC analysis enables dynamic tracking of

🩸 Platelets can carry tumor DNA. 🔹 Platelets – smallest yet 2nd most abundant blood cell type. 🔹New study: tumor-derived DNA found in platelets of advanced cancer patients. 🔹This cfDNA reservoir could complement plasma cfDNA, boosting detection sensitivity in low–tumor

Cancer cachexia = an underdiagnosed, lethal syndrome. · Affects up to 80% in pancreatic CA, 40% in lung. · It’s not just weight loss—think systemic inflammation, altered metabolism, fat/muscle wasting. · GDF-15, IL-6, activin A are key molecular drivers. · A major unmet need in

Liquid biopsies in #CRC 🩸 Serial MRD monitoring: ✔️Detects recurrence 8–11 months earlier than imaging ✔️Improves sensitivity from 40–50% to 80–90% ✔️Helps monitor ACT response Liquid tumor-agnostic assays are evolving: now integrating ✅Methylation ✅Fragmentomics

Humoral Immunity in CheckPoint Inhibitors Response CPI response isn't just T cell-driven. In a 374-patient CPI cohort, @Nature study shows: ✅ Broad, stable anti-exoproteome autoantibody signatures ✅Some AAbs enhance CPI efficacy (e.g., by blocking IL-6, IFN-I, TL1A) ✅Others

Esteban Cvitkovic (“Steve”, “El Gordo”) died on June 20, 2025. Inventor of hyperhydrated cisplatin, developer of oxaliplatin, pioneer in head and neck cancers.He had the rare gift of seeing the truth behind appearances and asking: “Is this practice truly useful to the patient?”

ctDNA/CTC-based liquid biopsies are redefining clinical oncology: enabling population screening, early relapse flagging, pharmacodynamic monitoring, and molecular profiling of resistance—all from peripheral blood. #Liquidbiopsies https://t.co/bqSDv5stqb

As of Jan 1, 2025, 18.6 million people in the U.S. are living with a history of cancer. By 2035, this is projected to exceed 22 million. Prostate, breast, & colorectal cancers lead prevalence. #Oncology #CancerSurvivorship https://t.co/7PcDYYalRx

#ASCO25 Development of acquired therapeutic resistance limits the efficacy of cancer treatments. How resistance arises, varies across cancer types & differs depending on therapeutic modalities. https://t.co/nP5CKljg6z

Radioligand therapies harness the cytotoxic force of radiotherapy with molecular precision—emerging as a new strategy for cancers. Clinical-stage radioligand therapies landscape overview #ASCO25 https://t.co/dW6ru4sFIk

🔍 Unmet Need in Localized Prostate Cancer 🌍 1.4M new global cases (2020) 🇺🇸 In the US: •65K Low Risk •108K Intermediate Risk •43K High Risk 🎯 Goal: therapies that prevent recurrence while preserving quality of life. 📉 Only ~43% receive radiotherapy #ASCO25

#ASCO25: We will present Phase Ill data, also published in @NEJM, for metastatic SCLC, offering a new option for this aggressive cancer, leveraging the use of T-cell engagers. https://t.co/n3Lg2HWtsN

Why add systemic therapy to radical surgery in NSCLC? 🧵 • Aim 1: ↑ cure by eradicating micrometastases (adj/neoadj) • Aim 2: Downstage tumor to enable resection • pCR ≈ surrogate for OS in chemo • TOX risk: 15–20% may not reach surgery ⚠️ CT ≠ ICB ≠ TKI #ASCO25

🚀#DLL3 innovation brought us to new frontiers in small cell lung cancer care. @Amgen’s T-cell engager technology is designed to activate the immune system to find & attack cancer cells that express DLL3. Discover how ⬇️ #ASCO25

mRNA pre-drugs: a new path in oncology drug design, with clear trade-offs. ✅ Lower production costs ✅ Extended antibody half-life ⚠️ New toxicities ⚠️ Reduced control over pharmacokinetics #ASCO25 #Oncology #DrugDevelopment #mRNAtherapeutics